BioELife Corp.
LITH · OTC
12/31/2018 | 12/31/2017 | 12/31/2016 | 12/31/2015 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.07 | -1.47 | -0.16 | 0.11 |
| FCF Yield | -11.54% | -4.15% | -3.52% | -4.00% |
| EV / EBITDA | -12.75 | -25.75 | -38.17 | -14.65 |
| Quality | ||||
| ROIC | 161.73% | -60.32% | 86.38% | 40.67% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.23 | 0.49 | 0.62 | 0.41 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | – | – |
| Free Cash Flow Growth | 37.16% | 8.82% | -301.14% | 9.29% |
| Safety | ||||
| Net Debt / EBITDA | -3.74 | -2.22 | -1.56 | -1.07 |
| Interest Coverage | -0.89 | -1.03 | -0.99 | -1.58 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -59,899.24 | -52,013.87 | 0.00 | 0.00 |